Thanks Rig…to you as well…🥳

NSAV....0098...Beauty Close here...🥳Break/Hold .0104 on Monday and we see .014 plus...imo...we shall see...
georgie18

Member Level
Re: None

Friday, May 10, 2024 2:31:57 PM

Post#
216475
of 216513
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...

NSAV....0098...Beauty Close here...🥳Break/Hold .0104 on Monday and we see .014 plus...imo...we shall see...
georgie18

Member Level
Re: None

Friday, May 10, 2024 2:31:57 PM

Post#
216475
of 216513
NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...

NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...

NSAV...0081s starting here...🥳...Gotta get through .0088 range and we see .01... https://schrts.co/rAGHFNhM ...

NSAV...008s clearing here...🥳

NSAV...008s getting tapped on the 4 mill ask block...🥳

PRST...1661... https://schrts.co/gQwkQbDx ...Bands Choking the PPS...🥳

PRST...1661... https://schrts.co/gQwkQbDx ...Bands Choking the PPS...🥳

SGMO...5605...Trying for Upper Bollie Breakout here...🥳

georgie18

Member Level
Re: None

Thursday, May 09, 2024 8:50:47 AM

Post#
380528
of 380553
SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.

“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”

The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.

Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.

SGMO...5605...Trying for Upper Bollie Breakout here...🥳

georgie18

Member Level
Re: None

Thursday, May 09, 2024 8:50:47 AM

Post#
380528
of 380553
SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.

“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”

The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.

Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.

NSAV...0079...Hit .0085...HOD...Looking for .01 Break again...🥳

TKMO...0006...Went Pink Current Today...now can we get some volume please...🥳

georgie18

Member Level
Re: None

Wednesday, May 08, 2024 1:46:41 PM

Post#
380522
of 380551
TKMO...0006 off the .0004 dip...62 Million Volume...https://www.sec.gov/Archives/edgar/data/1946585/000121390024040692/ea0205547-1aw_tekumo.htm

Thanks…🥳

Nice…🥳

SGN...Thanks for the heads up Mark...🥳

We shall ses...🥳

SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.

“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”

The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.

Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.

SGMO...49...NEWS...🥳...May 09, 2024 08:05 AM Eastern Daylight Time
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing. Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.

“Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field. We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo. “Using compact, protein-guided integrases built from Bxb1 variants as a means of targeted integration expands our genome editing abilities and capitalizes on the strength of Sangamo’s structural protein-DNA engineering capabilities to deliver potential genomic medicines to the patients who need them most.”

The MINT platform utilizes Bxb1, a serine recombinase, to integrate large sequences of DNA into the genome and is intended to avoid double stranded DNA breaks as well as the need for assistance from ancillary genome editing or DNA-repair modulating cargo. This flexible approach is cell-type agnostic, has been engineered to be simpler to manufacture than most other targeted integration technologies and is compatible with adeno-associated virus (AAV), lentiviral and lipid nanoparticle (LNP) delivery. With minimal dependence on cell DNA repair machinery, we believe the MINT platform carries a reduced translocation risk and our pre-clinical data have demonstrated high levels of on-target integration in certain locations.

Based on these initial findings, we believe the MINT platform could be deployed internally for neurology-focused indications, and could provide potential new collaboration opportunities, both for human disease and in agricultural biotech settings.

Doji Cross setting up and Bullish Psar Flip...🥳

NSAV...0072s up again...Big Block .0069 cleared here...🥳Ask thinned out...

ROMA...7609...Red to Green here...🥳

NSAV...0068...on the dip...1million share on top ask getting tapped here...🥳

That is very true...that just some of the rust I have to work off...lol...🥳

TKMO...0006 off the .0004 dip...62 Million Volume...https://www.sec.gov/Archives/edgar/data/1946585/000121390024040692/ea0205547-1aw_tekumo.htm

Thanks...🥳

TIVC...$1.17...was over $2 in the P/M...Perhaps it will fill that open gap...🥳...

georgie18

Member Level
Re: georgie18 post# 642560

Wednesday, May 08, 2024 9:22:05 AM

Post#
642566
of 642629
TIVC...$1.60 on the dip...Will hedge with bids at the gap...🥳

TIVC...$1.17...was over $2 in the P/M...Perhaps it will fill that open gap...🥳...

georgie18

Member Level
Re: georgie18 post# 642560

Wednesday, May 08, 2024 9:22:05 AM

Post#
642566
of 642629
TIVC...$1.60 on the dip...Will hedge with bids at the gap...🥳

MI...$8.93...Off my $6.57 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 642147

Tuesday, May 07, 2024 9:56:01 AM

Post#
642381
of 642624
MI...$7.80...Off my $6.57Alert...🥳...Hit $11.55 High yesterday...

georgie18

Member Level
Re: None

Friday, May 03, 2024 11:21:01 AM

Post#
642147
of 642379
MI...$6.57...Heavy Volume...on a Low Floater...I have no position at the moment...🥳

MI...$8.93...Off my $6.57 Alert...🥳

georgie18

Member Level
Re: georgie18 post# 642147

Tuesday, May 07, 2024 9:56:01 AM

Post#
642381
of 642624
MI...$7.80...Off my $6.57Alert...🥳...Hit $11.55 High yesterday...

georgie18

Member Level
Re: None

Friday, May 03, 2024 11:21:01 AM

Post#
642147
of 642379
MI...$6.57...Heavy Volume...on a Low Floater...I have no position at the moment...🥳

Hope so...🥳

Stop clogging the board...PLEASE...once in hour is enough...🥳

LMAO...I will tone it down...Now you know why I didn't want to start trading again...🥳Out for a bit...see y'all later...🥳

Out for a bit...see y'all later...🥳

TIVC...$1.60 on the dip...Will hedge with bids at the gap...🥳

TIVC...$1.60 on the dip...Will hedge with bids at the gap...🥳

Read the board and you will see...🥳

TIVC...$2.02...Off my $1.12...Alert...🥳

georgie18

Member Level
Re: None

Wednesday, April 24, 2024 7:18:24 AM

Post#
640982
of 642559
TIVC...$1.12... https://schrts.co/HUxnvFCr ...Bollie Squeeze setting up here...🥳1.5 Million Float...

TIVC...$2.02...Off my $1.12...Alert...🥳

georgie18

Member Level
Re: None

Wednesday, April 24, 2024 7:18:24 AM

Post#
640982
of 642559
TIVC...$1.12... https://schrts.co/HUxnvFCr ...Bollie Squeeze setting up here...🥳1.5 Million Float...

That's what it says...🥳